An observational study in Esophageal Cancer, sponsored by Centre Oscar Lambret. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-03.
Sponsored by Centre Oscar Lambret · Observational
The aim of this study is to identify prognostic factors for outcome in patients being complete clinical responders with chemoradiation or radiation for esophageal cancer
1,593 studies on the registry are indexed under Esophageal Neoplasms; 461 are open to participants now.
This study's enrollment of 110 is below the median of 200 across 341 observational studies indexed under Esophageal Neoplasms.
Browse Esophageal Neoplasms studies →Centre Oscar Lambret is the lead sponsor of 127 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patient treated for esophageal cancer in the Northern France Cancer Center from january 1998 to december 2003
Exclusion Criteria:
Chemotherapy according to standard
Radiotherapy according to local standard
Identification of prognostic factors for overall survival
Correlation between survival and baseline,clinical and treatment characteristics
Time frame: From date of treatment until death, assessed up to 10 years
Patterns of treatment failure
Type of recurrence : local, regional, distant.
Time frame: From date of treatment until treatment failure, assessed up to 10 years
Disease-free survival
Time between the end of treatment and the occurence of progression
Time frame: From date of treatment until progression or death, assessed up to 10 years
This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Oscar Lambret